Key clinical point: Combination quercetin and desferrioxamine could decrease iron overload in patients with transfusion-dependent beta-thalassemia major.
Major finding: Compared with placebo, combined therapy significantly improved high sensitivity C-reactive protein, ferritin, serum iron, transferrin, and transferrin saturation, but not tumor necrosis factor–alpha or total iron-binding capacity.
Study details: A randomized clinical trial of 84 patients with transfusion-dependent beta-thalassemia major.
Disclosures: The study was funded by the Iran University of Medical Sciences. The authors reported having no conflicts of interest.
Hezaveh ZS et al. Complement Ther Med. 2019;46:24-8.